How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.
Blood Cancer Discov
; 2(6): 562-567, 2021 11.
Article
em En
| MEDLINE
| ID: mdl-34778796
ABSTRACT
Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
COVID-19
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Blood Cancer Discov
Ano de publicação:
2021
Tipo de documento:
Article